Listed by the USPTO as JONES-FOSTER, ERICA NICOLE
Tech Center 1600 • Art Units: 1612 1644 1655 1656
This examiner grants 50% of resolved cases
JONES-FOSTER, ERICA NICOLE works in tech center 1600 and art unit 1612. Her record includes 91 resolved cases and a 50.5% allowance rate. The median time to allowance is 1281 days, indicating that applicants should plan for extended prosecution even though the outcome is close to an even split.
The interview lift is 37.7%. That association makes interviews a potentially useful tool for testing claim distinctions and narrowing disputes. Counsel should approach an interview with a specific resolution proposal and follow it with amendments or written clarification where appropriate.
The listed companies are Merck Sharp & Dohme LLC, Novozymes A/S, and Hanmi Pharm. Co., Ltd. The listed firms are MAIER & MAIER, PLLC, SUGHRUE MION, PLLC, and ARENTFOX SCHIFF LLP. These names provide context for recurring pharmaceutical applicants and representatives in the profile.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17185196 | GENETICALLY MODIFIED BACTERIAL CELLS AND METHODS USEFUL FOR PRODUCING TETRAMETHYL PYRAZINE | Final Rejection | The Regents of the University of California |
| 17267816 | DESIGNED, EFFICIENT AND BROAD-SPECIFICITY ORGANOPHOSPHATE HYDROLASES | Final Rejection | Yeda Research and Development Co. Ltd. |
| 17437232 | MICROBIAL TEST KIT, MICROBIAL TEST METHOD AND MICROBIAL TEST DEVICE | Non-Final OA | HITACHI HIGH-TECH CORPORATION |
| 17795939 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 17040448 | DEVICE FOR MANUFACTURING ORGANIC SUBSTANCE, AND GAS PROCESSING SYSTEM | Final Rejection | SEKISUI CHEMICAL CO., LTD. |
| 18031313 | CRISPR/CAS-BASED BASE EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION | Final Rejection | Duke University |
| 18245872 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | Final Rejection | SANOFI |
| 17299273 | Powder Detergent Compositions | Non-Final OA | Novozymes A/S |
| 18516310 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | Non-Final OA | Codexis, Inc. |
| 18578581 | RECOMBINANT YEAST CELL | Final Rejection | DANISCO US INC. |
| 17792670 | CONSORTIA OF MICROORGANISMS FOR SPATIAL AND TEMPORAL DELIVERY OF NITROGEN | Final Rejection | Pivot Bio, Inc. |
| 18030476 | METHODS AND COMPOSITIONS COMPRISING PD1 CHIMERIC POLYPEPTIDES | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | Final Rejection | HANMI PHARM. CO., LTD. |
| 18036538 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | Final Rejection | HANMI PHARM. CO., LTD. |
| 18562092 | A METHOD OF SEPARATING BISPECIFIC ANTIBODIES | Non-Final OA | Cytiva BioProcess R&D AB |
| 17945293 | PROBIOTICS FOR USE IN REDUCING THE INCIDENCE AND DURATION OF ILLNESS | Final Rejection | DUPONT NUTRITION BIOSCIENCES APS |
| 18534574 | BIOLOGICAL ENZYME FOR KILLING VIRUSES AND PREPARATION METHOD THEREOF | Final Rejection | Changde Jizhi Biological Technology Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.5% of resolved applications examined by Erica Nicole Jones-Foster were allowed (91 resolved cases), compared with 40.6% across Art Unit 1612 over the last five years.
This examiner's interview lift is +37.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Erica Nicole Jones-Foster took 1,281 days on average from filing to allowance.
Erica Nicole Jones-Foster examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).